Season 3 - Ep.3: Optimal management of angina - Artificial sweeteners and cardiovascular risk

6 snips

Oct 24, 2024

Guest

Marco Witkowski

Join experts Carlos Aguiar, a cardiology specialist, Christiaan Vrints from Antwerp University Hospital, and Marco Witkowski of Charité University, as they unpack critical insights on angina management. They discuss the latest ESC guidelines for chronic coronary syndromes and the importance of personalized treatment strategies. The conversation also delves into the cardiovascular risks associated with artificial sweeteners like erythritol, emphasizing the need for caution in using these alternatives, especially in vulnerable populations.

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 3min

Impact of Influenza and Diagnostic Advances in Heart Failure

02:57 • 5min

Risks of Artificial Sweeteners

07:39 • 5min

Navigating Angina: New Guidelines and Insights

12:38 • 4min

Personalized Management of Angina

16:43 • 8min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

Optimal management of angina

Artificial sweeteners and cardiovascular risk

Statistics Made Easy: Network meta-analyses

Host: Perry Elliott

Guests: Carlos Aguiar, Christiaan Vrints, Marco Witkowski

Want to watch that episode? Go to: https://esc365.escardio.org/event/1793

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Antonio Greco, Nicolle Kraenkel, Christiaan Vrints and Marco Witkowski have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.